ReviewCritical care (London, England)2008
The role of carbapenems in initial therapy for serious Gram-negative infections.
Review in Critical care (London, England), 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 45 citations in OpenAlex.
- Effects of different carbapenemase and siderophore production on cefiderocol susceptibility inAntimicrobial agents and chemotherapy · 2024Article
- Characterization and genetic analysis of extensively drug-resistant hospital acquired Pseudomonas aeruginosa isolates.BMC microbiology · 2024Article
- Carbapenem-ResistantCase reports in infectious diseases · 2023Article
- Article
- Emergence of plasmid-mediated colistin resistanceFrontiers in cellular and infection microbiology · 2022Article
- Article
- The Monte Carlo Simulation of Three Antimicrobials for Empiric Treatment of Adult Bloodstream Infections With Carbapenem-Resistant Enterobacterales in China.Frontiers in microbiology · 2021Article
- Xpert Carba-R assay for detection of carbapenemase-producing organisms in patients admitted to emergency rooms.Medicine · 2020Observational
- [Management of Carbapenem-resistant Enterobacteriaceae (CRE) infection in patients with hematological malignancies: Chinese consensus (2020)].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2020Article
- Evaluation of the susceptibility test of polymyxin B using the commercial test Policimbac®.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2020Article
- In vitro evaluation of double carbapenem and colistin combinations against OXA-48, NDM carbapenemase-producing colistin-resistant Klebsiella pneumoniae strains.Antimicrobial resistance and infection control · 2020Article
- Clinical Observation and Prognostic Analysis of Patients WithFrontiers in cellular and infection microbiology · 2020Article
- Prevalence of metallo-β-lactamase acquired genes among carbapenems susceptible and resistant Gram-negative clinical isolates using multiplex PCR, Khartoum hospitals, Khartoum Sudan.BMC infectious diseases · 2018Article
- Integrated pharmacokinetic-pharmacodynamic modeling to evaluate empiric carbapenem therapy in bloodstream infections.Infection and drug resistance · 2018Article
- In vitro pharmacodynamics of various antibiotics in combination against extensively drug-resistant Klebsiella pneumoniae.Antimicrobial agents and chemotherapy · 2015Article
- Optimizing the use of carbapenems in the face of increasing Gram-negative resistance.Critical care (London, England) · 2008Article
- Antibiotic susceptibility pattern of Enterobacteriaceae and non-fermenter Gram-negative clinical isolates of microbial resource orchid.Journal of natural science, biology, and medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The treatment of patients with serious Gram-negative infections must be both prompt and correct. Numerous studies have demonstrated that mortality risk is significantly increased when the initial antibiotic regimen does not adequately cover the infecting pathogen. Furthermore, changing to an appropriate regimen once culture results are available does not reduce this risk. Therefore, one must empirically treat serious infections with a regimen that covers likely pathogens. Selecting such a regimen is complicated by the increasing prevalence of resistance to commonly used antibiotics. Moreover, multidrug-resistant pathogens, once limited to hospital-acquired infections, are increasingly being detected in community-acquired infections, especially those involving the urinary and gastrointestinal tracts or in immunocompromised patients. Consequently, the initial antibiotic regimen must have a broad spectrum of activity that includes potential resistant pathogens, as indicated by the local antibiogram. Many multidrug-resistant pathogens remain susceptible to carbapenems despite increasing worldwide antibiotic resistance. This article reviews the role played by carbapenems in the initial treatment of serious Gram-negative infections and the potential effect of emerging resistance on this role.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.